{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:52:59Z","timestamp":1781643179019,"version":"3.54.5"},"reference-count":51,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>CD22 is a membrane glycophosphoprotein found on nearly all healthy B-lymphocytes and most B-cell lymphomas. Recent in vitro studies have identified several anti-CD22 monoclonal antibodies (mAbs) that block the interaction of CD22 with its ligand. One of these mAbs, HB22.7, has been shown to effectively induce apoptosis in several B-cell lymphoma cell lines. Lymphoma xenograft studies with Raji-xenograft mice were used to assess the toxicity and efficacy of HB22.7 alone and with combined modality immunotherapy (CMIT) with yttrium 90Y-DOTA-peptide-Lym-1 radioimmunotherapy (RIT). The effect of the sequence of these agents on the combined treatment was assessed by administering HB22.7 24 hours before, simultaneously with, or 24 hours after RIT. Within the groups treated with RIT alone or with RIT and HB22.7 (CMIT), the reduction in tumor volume was the greatest when HB22.7 was administered simultaneously with and 24 hours after RIT, and in the RIT treatment groups, this translated into the greatest overall response and survival, respectively. Overall survival rates at the end of the 84-day CMIT trial were 67% and 50% in the groups treated with HB22.7 simultaneously and 24 hours after RIT, respectively. This compared favorably with the untreated and the RIT alone groups, which had survival rates of 38% and 43% at the end of the trial. Surprisingly, when compared with untreated controls and all other treatment groups, the greatest cure and overall survival rates were observed in the group treated with HB22.7 alone, with 47% cured and 76% surviving at the end of the 84-day trial. RIT clearance was not affected by treatment with HB22.7. When compared with RIT alone, there was no significant additional hematologic (white blood cell, red blood cell, or platelet count) toxicity when HB22.7 was added to RIT. Nonhematologic toxicity (assessed as change in body weight) was also unchanged when HB22.7 was added to RIT. Thus the anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts without significant toxicity.<\/jats:p>","DOI":"10.1182\/blood-2002-08-2629","type":"journal-article","created":{"date-parts":[[2003,4,21]],"date-time":"2003-04-21T13:30:06Z","timestamp":1050931806000},"page":"3641-3647","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts"],"prefix":"10.1182","volume":"101","author":[{"given":"Joseph M.","family":"Tuscano","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laird A.","family":"Miers","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Kroger","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kukis","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Lamborn","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Tedder","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald L.","family":"DeNardo","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, University of California, Davis Medical Center, Sacramento; Veterans Administration of Northern California Health Care System; Duke University Medical Center, Durham, NC; and Brain Tumor Research Center, University of California, San Francisco."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822171773100_B1","first-page":"1317","article-title":"Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.","volume":"40","author":"DeNardo","year":"1999","journal-title":"J Nucl Med."},{"key":"2019111822171773100_B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/cbr.1998.13.213","article-title":"A revolution in the treatment of non-Hodgkin's lymphoma.","volume":"13","author":"DeNardo","year":"1998","journal-title":"Cancer Biother Radiopharm."},{"key":"2019111822171773100_B3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.44.1.43","article-title":"New developments in monoclonal antibodies for cancer detection and therapy.","volume":"44","author":"Goldenberg","year":"1994","journal-title":"CA Cancer J Clin."},{"key":"2019111822171773100_B4","first-page":"459","article-title":"Targeted therapy of cancer with radiolabeled antibodies.","volume":"329","author":"Goldenberg","year":"1993","journal-title":"J Nucl Med."},{"key":"2019111822171773100_B5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody.","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111822171773100_B6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1053-4296(05)80030-X","article-title":"Radioimmunotherapy of the non-Hodgkin's lymphomas.","volume":"5","author":"Knox","year":"1995","journal-title":"Semin Radiat Oncol."},{"key":"2019111822171773100_B7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 131I-B-1 (anti-CD20) antibody therapy with autologous stem cell transplantation of relapsed B cell lymphomas.","volume":"346","author":"Press","year":"1995","journal-title":"Lancet."},{"key":"2019111822171773100_B8","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.","volume":"16","author":"DeNardo","year":"1998","journal-title":"J Clin Oncol."},{"key":"2019111822171773100_B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cbr.1998.13.239","article-title":"Low-dose fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.","volume":"13","author":"DeNardo","year":"1998","journal-title":"Cancer Biother Radiopharm."},{"key":"2019111822171773100_B10","first-page":"1014","article-title":"Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.","volume":"50(suppl 3)","author":"DeNardo","year":"1990","journal-title":"Cancer Res."},{"key":"2019111822171773100_B11","first-page":"3292S","article-title":"Pharmacokinetics, dosimetry and initial therapeutic results with 131l- and 111In-90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (mAb) in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL).","volume":"5","author":"Juweid","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2019111822171773100_B12","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131\u2013anti-B1 radioimmunotherapy for B-cell lymphoma.","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol."},{"key":"2019111822171773100_B13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s002620050512","article-title":"Pharmacokinetics and biodistribution of radioimmunoconjugugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy.","volume":"47","author":"Li","year":"1998","journal-title":"Cancer Immunol Immunother."},{"key":"2019111822171773100_B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/sj.leu.2402320","article-title":"Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.","volume":"16","author":"Ma","year":"2002","journal-title":"Leukemia."},{"key":"2019111822171773100_B15","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+B-cell non-Hodgkin's lymphoma.","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol."},{"key":"2019111822171773100_B16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s002620050299","article-title":"Lymphoma-selective antibody LYM-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.","volume":"43","author":"Rose","year":"1996","journal-title":"Cancer Immunol Immunother."},{"key":"2019111822171773100_B17","first-page":"2779","article-title":"Maximum tolerated dose of 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.","volume":"18","author":"DeNardo","year":"1998","journal-title":"Anticancer Res."},{"key":"2019111822171773100_B18","first-page":"302","article-title":"67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.","volume":"40","author":"DeNardo","year":"1999","journal-title":"J Nucl Med."},{"key":"2019111822171773100_B19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/cbr.1998.13.351","article-title":"Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.","volume":"13","author":"O'Donnell","year":"1998","journal-title":"Cancer Biother Radiopharm."},{"key":"2019111822171773100_B20","first-page":"3647","article-title":"A phase I study of 90Y\u20132IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.","volume":"20","author":"O'Donnell","year":"2000","journal-title":"Anticancer Res."},{"key":"2019111822171773100_B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"A randomized trial comparing chemotherapy alone to chemotherapy followed by radiotherapy for localized intermediate grade non-Hodgkin's lymphoma.","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med."},{"key":"2019111822171773100_B22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jnci\/84.6.399","article-title":"Dose escalation of radioantibody in a mouse model with the use of recombinant human IL-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.","volume":"84","author":"Blumenthal","year":"1992","journal-title":"J Natl Cancer Inst."},{"key":"2019111822171773100_B23","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1097-0142(19940201)73:3+<1038::AID-CNCR2820731343>3.0.CO;2-8","article-title":"Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.","volume":"73(suppl 3)","author":"DeNardo","year":"1994","journal-title":"Cancer."},{"key":"2019111822171773100_B24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Riadiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support.","volume":"329","author":"Pres","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111822171773100_B25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0969-8051(93)90025-P","article-title":"Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs.","volume":"20","author":"Vriesendorp","year":"1993","journal-title":"Nucl Med Biol."},{"key":"2019111822171773100_B26","first-page":"2483","article-title":"Comparison of DOTA-peptide-ChL6, a novel immunococonjugate with catabolizable linker to 2IT-BAD-Chl6 in breast cancer xenografts.","volume":"4","author":"DeNardo","year":"1998","journal-title":"Clin Cancer Res."},{"key":"2019111822171773100_B27","first-page":"1735","article-title":"Yttrium-90\/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.","volume":"17","author":"DeNardo","year":"1997","journal-title":"Anticancer Res."},{"key":"2019111822171773100_B28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/cbr.2000.15.71","article-title":"Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.","volume":"15","author":"DeNardo","year":"2000","journal-title":"Cancer Biother Radiopharm."},{"key":"2019111822171773100_B29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jnci\/84.6.374","article-title":"Enhancement of clinical radioimmunotherapy for cancer and the role cytokines [editorial].","volume":"84","author":"DeNardo","year":"1992","journal-title":"J Natl Cancer Inst."},{"key":"2019111822171773100_B30","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1073\/pnas.94.8.4000","article-title":"Synergy of Taxol and radioimmunotherapy with yttrium-90 labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.","volume":"94","author":"DeNardo","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111822171773100_B31","first-page":"144","article-title":"Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus [see comments].","volume":"3","author":"Forastire","year":"1997","journal-title":"Cancer J Sci Am."},{"key":"2019111822171773100_B32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/jama.1990.03450110090034","article-title":"NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer.","volume":"264","year":"1990","journal-title":"JAMA."},{"key":"2019111822171773100_B33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","article-title":"Epidermoid anal cancer: treatment by radiation alone or by radiation and 5fluorouracil with and without mitomycin C [see comments].","volume":"21","author":"Cummings","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2019111822171773100_B34","first-page":"113","article-title":"Chemoradiotherapy in non-small cell lung cancer: paclitaxel\/carboplatin\/radiotherapy in regionally advanced disease.","volume":"23","author":"Belani","year":"1996","journal-title":"Semin Oncol."},{"key":"2019111822171773100_B35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7326\/0003-4819-125-9-199611010-00003","article-title":"Chemotherapy plus radiotherapy compared to radiotherapy alone in the treatment of local advanced, unresectable non-small cell lung cancer.","volume":"125","author":"Pritchard","year":"1996","journal-title":"Ann Intern Med."},{"key":"2019111822171773100_B36","first-page":"4011","article-title":"Synergistic therapy of breast cancer with Y-90chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.","volume":"18","author":"DeNardo","year":"1998","journal-title":"Anticancer Res."},{"key":"2019111822171773100_B37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/08830180109045588","article-title":"CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction.","volume":"20","author":"Poe","year":"2001","journal-title":"Int Rev Immunol."},{"key":"2019111822171773100_B38","first-page":"195","article-title":"Receptor modulators of B-cell receptor signaling\u2014CD19\/CD22.","volume":"245","author":"Smith","year":"2000","journal-title":"Curr Top Microbiol Immunol."},{"key":"2019111822171773100_B39","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/eji.1830260610","article-title":"Involvement of p72syk kinase, p53\/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22.","volume":"26","author":"Tuscano","year":"1996","journal-title":"Eur J Immunol."},{"key":"2019111822171773100_B40","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood.V87.11.4723.bloodjournal87114723","article-title":"Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22\/CD22L interactions impairs T-cell proliferation.","volume":"87","author":"Tuscano","year":"1996","journal-title":"Blood."},{"key":"2019111822171773100_B41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/smim.1998.0121","article-title":"CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.","volume":"10","author":"Sato","year":"1998","journal-title":"Semin Immunol."},{"key":"2019111822171773100_B42","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V94.4.1382","article-title":"CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK\/SAPK signaling cascade.","volume":"94","author":"Tuscano","year":"1999","journal-title":"Blood."},{"key":"2019111822171773100_B43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/cbr.1998.13.351","article-title":"Combined modality radioimmunotherapy with Taxol and 90Y-LYM-1 for Raji lymphoma xenografts.","volume":"13","author":"O'Donnell","year":"1998","journal-title":"Cancer Biother Radiopharm."},{"key":"2019111822171773100_B44","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1749-6632.1949.tb27297.x","article-title":"The attractions of proteins for small molecules and ions.","volume":"51","author":"Scatchard","year":"1947","journal-title":"Ann N Y Acad Sci."},{"key":"2019111822171773100_B45","first-page":"71","article-title":"Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji).","volume":"3","author":"DeNardo","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2019111822171773100_B46","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/1097-0142(19940201)73:3+<1012::AID-CNCR2820731340>3.0.CO;2-0","article-title":"Comparative toxicity studies of yttrium-90MX-DTPA and 2IT-BAD conjugated monoclonal antibody (BRE-3).","volume":"73","author":"DeNardo","year":"1994","journal-title":"Cancer."},{"key":"2019111822171773100_B47","first-page":"216","article-title":"A phase I clinical study of 111In\/90Y\u20132IT-BAD-Lym-1 for non-Hodgkin's lymphoma (NHL) [abstract].","volume":"40","author":"O'Donnell","year":"1999","journal-title":"J Nucl Med."},{"key":"2019111822171773100_B48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0959-437X(01)00258-1","article-title":"The JNK signal transduction pathway.","volume":"12","author":"Weston","year":"2002","journal-title":"Curr Opin Genet Dev."},{"key":"2019111822171773100_B49","doi-asserted-by":"crossref","first-page":"31929","DOI":"10.1074\/jbc.271.50.31929","article-title":"The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation: duration of JNK activation may determine cell death and proliferation.","volume":"271","author":"Chen","year":"1996","journal-title":"J Biol Chem."},{"key":"2019111822171773100_B50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0167-8140(98)00007-3","article-title":"The role of the stress-activated protein kinase (SAPK\/JNK) signaling pathway in radiation-induced apoptosis.","volume":"47","author":"Verheij","year":"1998","journal-title":"Radiother Oncol."},{"key":"2019111822171773100_B51","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.4049\/jimmunol.165.10.5588","article-title":"Regulation of MHC class II signal transduction by the B cell coreceptors CD19 and CD22.","volume":"165","author":"Bobbitt","year":"2000","journal-title":"J Immunol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/9\/3641\/1255400\/h80903003641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/9\/3641\/1255400\/h80903003641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:17:39Z","timestamp":1574115459000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/9\/3641\/105764\/AntiCD22-ligandblocking-antibody-HB227-has"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-08-2629","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}